Phenominer Database Results (49 results)

 
 
Table "column sort" updates the order of the bars in the chart.
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Value Units SEM SD Method Method Site Method Duration Post Insult Type Post Insult Time Value Post Insult Time Unit Method Notes Clinical Measurement Notes Record ID Study ID
DA.ACI-(D10Rat15-D10Rat29) percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 8 62.5 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67855 829
DA.ACI-(D10Rat15-D10Rat29) percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 10 40.0 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67856 829
DA.ACI-(D10Rat2-D10Rat6) percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 8 100.0 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67860 829
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103.0 days-131.0 days 12 50.0 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 68710 839
DA.ACI-(D10Rat2-D10Rat29)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 7 14.3 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68734 829
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 16 50.0 % in vivo visual assessment 0.0 subcutaneous injection 40 days from 8 to 40 days 69384 892
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 18 94.0 % in vivo visual assessment 0.0 subcutaneous injection 38 days from 8 to 38 days 69390 892
DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 7 100.0 % in vivo visual assessment 0.0 subcutaneous injection 40 days from 8 to 40 days 69412 892
DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (30 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait male 91.0 days-112.0 days 21 76.0 % in vivo visual assessment 0.0 visual observation 69488 837
DA.PVG.1AV1-(D4Got126-D4Got136) percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug/200 ul) Jagodic M, et al., J Immunol 2005 Jan 15;174(2):918-24. central nervous system integrity trait both 63.0 days-150.0 days 21 100.0 % in vivo visual assessment 0.0 intradermal injection from p.i. day 7 DA.PVG.1AV1-(D4Got128-D4Got136) for strain 68130 838
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 10 80.0 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67849 829
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 8 100.0 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67850 829
DA.ACI-(D10Rat2-D10Rat29)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103.0 days-131.0 days 10 30.0 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 68718 839
DA.ACI-(D10Rat2-D10Rat29)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103.0 days-131.0 days 10 0.0 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 68722 839
DA.ACI-(D10Rat2-D10Rat29)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103.0 days-131.0 days 7 14.0 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 68726 839
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 10 100.0 % in vivo visual assessment 0.0 subcutaneous injection 40 days from 8 to 40 days 69409 892
DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 10 30.0 % in vivo visual assessment 0.0 subcutaneous injection 34 days from 8 to 34 days 69426 892
DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (15-22 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 91.0 days-112.0 days 13 69.0 % in vivo visual assessment 0.0 68123 837
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (0.09 ug/g) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 91.0 days-112.0 days 89.0 % 33.0 in vivo visual assessment 0.0 visual observation 69497 837
DA.ACI-(D10Rat219-D10Rat29) percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 16 81.2 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67874 829
DA.ACI-(D10Rat12-D10Rat144) percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 13 53.8 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67876 829
N:HS percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (50-120 ug) and Freund's complete adjuvant (100 ul) Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 central nervous system integrity trait both 132.0 days-177.0 days 217 41.0 % in vivo visual assessment 0.0 66040 114
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 16 87.5 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67852 829
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103.0 days-131.0 days 10 80.0 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 68714 839
DA.ACI-(D10Rat2-D10Rat29)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103.0 days-131.0 days 8 0.0 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 68724 839
DA.ACI-(D10Rat2-D10Rat29)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 8 75.0 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68735 829
ACI/SegHsd percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (0.25 mg/ml) and Freund's incomplete adjuvant (50 %) Dahlman I, et al., Hum Mol Genet 1999 Nov;8(12):2183-90. central nervous system integrity trait not specified 70.0 days-145.0 days 21 5.0 % in vivo visual assessment 0.0 69970 1279
DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 11 91.0 % in vivo visual assessment 0.0 subcutaneous injection 38 days from 8 to 38days 69406 892
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (30 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait male 91.0 days-112.0 days 22 82.0 % in vivo visual assessment 0.0 visual observation 69487 837
DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (0.1 ug/g) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 91.0 days-112.0 days 69.0 % 48.0 in vivo visual assessment 0.0 visual observation 69498 837
DA.PVG.1AV1-(D4Got126-D4Got136) percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug/200 ul) Jagodic M, et al., J Immunol 2005 Jan 15;174(2):918-24. central nervous system integrity trait both 63.0 days-150.0 days 19 10.0 % in vivo visual assessment 0.0 intradermal injection from p.i. day 7 DA.PVG.1AV1-(D4Got128-D4Got136) for strain 68126 838
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug/200 ul) Jagodic M, et al., J Immunol 2005 Jan 15;174(2):918-24. central nervous system integrity trait both 63.0 days-150.0 days 23 100.0 % in vivo visual assessment 0.0 intradermal injection from p.i. day 7 68128 838
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 16 87.5 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67853 829
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103.0 days-131.0 days 11 100.0 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 68132 839
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103.0 days-131.0 days 10 80.0 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 68706 839
DA/Ztm percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (0.25 mg/ml) and Freund's incomplete adjuvant (50 %) Dahlman I, et al., Hum Mol Genet 1999 Nov;8(12):2183-90. central nervous system integrity trait not specified 70.0 days-145.0 days 36 72.0 % in vivo visual assessment 0.0 69969 1279
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 37 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 28 64.0 % in vivo visual assessment 0.0 subcutaneous injection 37 days from 8 to 37 days 69378 892
DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 24 33.0 % in vivo visual assessment 0.0 subcutaneous injection 37 days from 8 to38 days 69379 892
DA.PVG.1AV1-(D4Got211-D4Mit12)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 19 100.0 % in vivo visual assessment 0.0 subcutaneous injection 31 days from 8 to 31days 69397 892
DA.PVG.1AV1-(D4Rat23-D4Mit12)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 14 86.0 % in vivo visual assessment 0.0 subcutaneous injection 40 days from 8 to 40 days 69415 892
DA.ACI-(D10Rat10-D10Rat142) percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 7 85.7 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67875 829
DA.ACI-(D10Rat15-D10Rat29) percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 12 33.3 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67848 829
DA.ACI-(D10Rat15-D10Rat29) percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 13 76.9 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67859 829
DA.PVG.1AV1-(D4Got211-D4Mit12)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 16 38.0 % in vivo visual assessment 0.0 subcutaneous injection 40 days from 8 to 40 days 69387 892
DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 10 90.0 % in vivo visual assessment 0.0 subcutaneous injection 31 days from 8 to 31days 69394 892
DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 6 50.0 % in vivo visual assessment 0.0 subcutaneous injection 34 days from 8 to 34 days 69435 892
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (15-22 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 91.0 days-112.0 days 12 92.0 % in vivo visual assessment 0.0 68122 837
DA.ACI-(D10Rat219-D10Rat29) percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 10 60.0 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67873 829
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug/200 ul) Jagodic M, et al., J Immunol 2005 Jan 15;174(2):918-24. central nervous system integrity trait both 63.0 days-150.0 days 20 60.0 % in vivo visual assessment 0.0 intradermal injection from p.i. day 7 68124 838